Open AccessXuebijing injection alleviates liver injury in patients with hepatocellular carcinoma by inhibiting inflammatory response after transarterial chemoembolization
Author(s) -
Zhong Chen,
Feng Cao
Publication year - 2022
Publication title -
tropical journal of pharmaceutical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.209
H-Index - 36
eISSN - 1596-5996
pISSN - 1596-9827
DOI - 10.4314/tjpr.v20i8.22
Subject(s) - medicine , hepatocellular carcinoma , liver injury , inflammation , white blood cell , gastroenterology , liver cancer , bilirubin , hepatic dysfunction , transcatheter arterial chemoembolization , peripheral blood , pharmacology
Purpose: To study the influence of Xuebijing (XBJ) injection on patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE), and to elucidate the underlying mechanism of action.
Methods: Thirty-nine HCC patients were retrospectively analyzed. They were assigned to 3 groups: negative group which received no XBJ injection, low-dose XBJ group given XBJ injection (50 ml), and high-dose XBJ group given 100 mL of XBJ injection. Peripheral blood was separately collected andanalyzed on the first day after admission and TACE.
Results: TACE led to liver damage in HCC patients, with increased serum activities of ALT and AST, and total bilirubin (tBLB). Moreover, TACE elevated white blood cells, neutrophil count, C-reactive protein (CRP) and expression levels of inflammation cytokines. In the groups treated with XBJ injection,there were dose-dependent mitigation of liver dysfunction, and reduced levels of inflammatory cytokines, when compared with the negative group. However, XBJ injection did not affect myelosuppression or regulatory T cells.
Conclusion: XBJ dose-dependently decreases liver injury in HCC patients after TACE by suppressing inflammatory response. Thus, XBJ may exert hepatoprotective effect on HCC after TACE in humans in clinical practice.